Coherus BioSciences

$18.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+1.65%) Today
$0.00 (0.00%) As of 7:08 AM EST after-hours

Why Robinhood?

You can buy or sell CHRS and other stocks, options, and ETFs commission-free!

About CHRS

Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA. The listed name for CHRS is Coherus BioSciences, Inc. Common Stock.

CEO
Denny M. Lanfear
Employees
291
Headquarters
Redwood City, California
Founded
2010
Market Cap
1.33B
Price-Earnings Ratio
9.26
Dividend Yield
Average Volume
787.44K
High Today
$18.57
Low Today
$18.15
Open Price
$18.48
Volume
632.94K
52 Week High
$23.03
52 Week Low
$10.86

Collections

CHRS Earnings

-$0.46
-$0.04
$0.39
$0.81
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, After Hours

You May Also Like